SEMICONDUCTOR NANOPARTICLE COMPOSITE FILM, COMPOSITE BASE AND DEVICE INCLUDING THE SAME, AND METHOD FOR MANUFACTURING SEMICONDUCTOR NANOPARTICLE COMPOSITE FILM
The present disclosure relates to a semiconductor nanoparticle composite film including semiconductor nanoparticles and diamond-like carbon (DLC), the composite film satisfying at least one selected from the group consisting of: i) the composite film includes mainly the semiconductor nanoparticles; and ii) at least a portion of the semiconductor nanoparticles are arranged in line. The composite film can be obtained by, for example, irradiating a semiconductor nanoparticle-containing film including semiconductor nanoparticles and a carbon source with an ion beam to generate DLC. The carbon source includes an organic compound other than a polymer.
This state estimation device estimates a state of each point of a partial point group, which is a finite part of a point group structure in which one or more types of points spread infinitely through a space, by using, as input, a type and position of each point of the partial point group. The state estimation device includes: an acquisition unit that acquires a type and position of an input point as input information; and a state estimation unit that estimates a feature vector corresponding to the input information by a state estimation model that is a trained model obtained by machine learning a correspondence relationship between the type and position of a point in the partial point group and a feature vector representing a state of each point of the partial point group.
The present invention provides a computer program or the like, capable of improving the utilization degree of a detection signal detected by using an optical sensor. A computer program according to one aspect of the present disclosure causes a computer to execute processing for: acquiring a first profile indicating a change in interaction between substances detected by using an optical sensor; Fourier-transforming the acquired first profile to acquire a spectrum for each frequency; inverse-Fourier-transforming the spectrum of a specific frequency among the acquired spectra for the respective frequencies to generate a second profile; and acquiring a classification of a group to which the second profile belongs when the second profile has been classified into a plurality of groups.
G01N 21/41 - RefractivityPhase-affecting properties, e.g. optical path length
G01N 21/45 - RefractivityPhase-affecting properties, e.g. optical path length using interferometric methodsRefractivityPhase-affecting properties, e.g. optical path length using Schlieren methods
4.
INFORMATION PROCESSING METHOD, LEARNING MODEL GENERATION METHOD, LEARNING MODEL, COMPUTER PROGRAM, AND INFORMATION PROCESSING DEVICE
Provided are an information processing method, a learning model generation method, a learning model, a computer program, and an information processing device. In the present invention, a computer executes processing wherein: data of an adaptive immune receptor of a subject is acquired; a calculation based on the acquired data of the adaptive immune receptor of the subject is executed using a learning model trained to output information on a disease estimated from an adaptive immune receptor on the basis of data of the adaptive immune receptor; and information on a disease inferred from the adaptive immune receptor of the subject on the basis of the calculation result executed using the learning model is output.
Provided are a method for manufacturing a three-dimensional-shaped article and an ink set for production of a three-dimensional-shaped article which make it possible to manufacture a three-dimensional-shaped article with good shaping precision, even when manufacturing a three-dimensional-shaped article that has a complex shape and that is made from a soft material, for example. The present invention relates to a method for manufacturing a three-dimensional-shaped article, said method comprising: a step for respectively discharging (a) a model material ink which contains an ion-crosslinkable polymer and (b) a support material ink which contains a support material and a crosslinking factor; a step for curing the discharged ion-crosslinkable polymer; and a step for removing a shaped article of the support material ink.
[Problem] The problem addressed is to discover clinically useable non-invasive index that makes it possible to predict the effect of combination therapy by multiple drugs, including immune checkpoint inhibitors, in hepatocellular carcinoma. [Solution] Using the peripheral blood of a hepatocellular carcinoma patient as a sample, the effect of combination therapy by multiple drugs, including immune checkpoint inhibitors, is predicted by a test method that includes at least one of steps (a)-(d). For example, the effect of combination therapy by an immune checkpoint inhibitor and an angiogenesis inhibitor is predicted. Preferably, the method includes a step for comparing the measured value with a reference value. (a) A step for measuring the relative cell count of CD14+ cells, (b) a step for measuring the expression level of a gene such as FABP5 in CD14+ cells, (c) a step for measuring the relative cell count of CD4+ cells that are positive for CCR7, etc., (d) a step for measuring the expression level of a gene such as FOS in CD4+ cells.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
7.
WELDED JOINT, WELDED STRUCTURE, AND WELDING METHOD
According to this welded joint, welded structure, and welding method, a welded joint formed between steel plates of which the ends are butted against each other comprises a first welding layer and a second welding layer that is stacked on the first welding layer and is adjacent to the surface of the steel plates. The first welding layer has arrestability for suppressing propagation of brittle cracks, and the second welding layer has SCC resistance for suppressing stress corrosion cracking (SCC) caused by a fluid in contact with the surface of the steel plates.
B23K 31/00 - Processes relevant to this subclass, specially adapted for particular articles or purposes, but not covered by any single one of main groups
A computer-readable recording medium storing therein a program for causing a computer to execute a process including: obtaining constraint conditions forming a 0-1 integer programming problem including variables each taking a value 0 or 1, each constraint condition including at least one of the variables; identifying pairings of a variable appearing only in a predetermined number of constraint conditions and the constraint conditions where the variable appears, the predetermined number being less than a total number of the constraint conditions; registering, in a storage unit, for each of the identified pairings, first correlation information correlating the variable of the pairing with another variable appearing in at least one of the constraint conditions of the pairing; registering, in the storage unit, second correlation information correlating, based on a degree of relationship between the variables, at least one of the variables and another variable having at least a predetermined degree of relationship with the at least one variable; and searching for a solution to the 0-1 integer programming problem by determining, based on the first and second correlation information, a group of any two or more correlated variables, for value inversion.
This electron beam irradiation device includes: a disposition part for disposing an irradiation target including a photosensitive substance on the inside; and an irradiation unit for emitting an electron beam with energy higher than 1 MeV towards the photosensitive substance inside the irradiation target disposed on the disposition part. The irradiation unit causes the photosensitive substance to react by irradiating the photosensitive substance with the electron beam, and also causes Cherenkov light to be radiated due to propagation of the electron beam in the irradiation target and causes the photosensitive substance to react due to the Cherenkov light.
Porous particles according to the present invention contain a starch that is modified with an organic acid. The organic acid is a polyvalent carboxylic acid having at least three carboxylate groups per molecule, or a salt thereof. The porous particles according to the present invention are entirely composed of a biodegradable material, and can, when being discarded, reduce the influence on the environmental load. The porous particles of the present invention are useful as a material for sanitary products and agricultural materials, for example.
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01J 20/30 - Processes for preparing, regenerating or reactivating
The present disclosure provides: a method for producing regulatory T (Treg) cells, the method including a step for suppressing the activity of RBPJ in conventional T (Tconv) cells; and Treg cells produced by the method. The present disclosure also provides a drug for inducing Treg cells that can be used in the method of the present disclosure. The present disclosure further provides a drug for immunosuppression, comprising Treg cells produced by the method of the present disclosure or a drug for inducing Treg cells. Drugs for immunosuppression of the present disclosure are useful in the treatment of autoimmune diseases and tissue transplant patients.
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 5/14 - Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
A sterilization device (1) includes a peroxynitric acid gas generation section (10) and a sterilization treatment section (20). The peroxynitric acid gas generation section (10) generates peroxynitric acid gas obtained by gasifying a peroxynitric acid-containing liquid. In so doing, for example, the peroxynitric acid gas generation section (10) generates a peroxynitric acid mist by ultrasonically atomizing the peroxynitric acid-containing and causes the liquid, peroxynitric acid gas to be generated from the peroxynitric acid mist. The sterilization treatment section (20) applies the peroxynitric acid gas to a sterilization target (22) to sterilize the sterilization target (22).
National Institute of Advanced Industrial Science and Technology (Japan)
Inventor
Fujita, Katsumasa
Bando, Kazuki
Liu, Li
Li, Junjun
Sawa, Yoshiki
Miyagawa, Shigeru
Nawa, Yasunori
Fujita, Satoshi
Abstract
Method for evaluating cardiomyocytes using Raman scattering: a Raman spectrum of cardiomyocytes artificially induced to differentiate from pluripotent stem cells is acquired, an intensity of Raman-scattered light for a protein containing at least one of heme b and heme c as a prosthetic group is acquired from the Raman spectrum, and a state of progress of maturation of the cardiomyocytes is evaluated on the basis of the intensity of the Raman-scattered light. Method for evaluating differentiation into cardiomyocytes using Raman scattering: cells which are pluripotent stem cells are artificially induced to differentiate into cardiomyocytes, a Raman spectrum of the cells induced to differentiate is acquired, an intensity of Raman-scattered light for at least one of heme b and heme c is acquired from the Raman spectrum, and a state of progress of differentiation of the cells into cardiomyocytes is evaluated on the basis of the intensity of the Raman-scattered light.
Provided is an atom concentration device that comprises a molecular beam radiation unit that radiates a molecular beam that includes specific atoms, a laser light source unit that radiates a laser that has a wavelength that excites the specific atoms, and a reflection unit that includes a plurality of mirrors that reflect the laser. The laser light source unit radiates the laser to satisfy a condition under which the specific atoms undergo Rabi oscillation at the reflection unit.
EDUCATIONAL FOUNDATION OF OSAKA MEDICAL AND PHARMACEUTICAL UNIVERSITY (Japan)
Inventor
Jingushi Kentaro
Tsujikawa Kazutake
Miyamoto Shunsuke
Taniguchi Kohei
Komura Kazumasa
Tanaka Tomohito
Omichi Masahide
Abstract
Provided is a biomarker useful for diagnosis of platinum preparation resistance. Also provided is an examination method for determining platinum preparation resistance using the biomarker. Attention is paid to an EV released from an excised tissue of a cancer site as an EV derived from only a lesion site reflecting the in vivo environment, and it was found that the EV released from the ovarian cancer tissue has a characteristic RNA modification different from that of the EV released from the normal ovarian tissue.
THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY (Japan)
Inventor
Hirai, Toshiro
Yoshioka, Yasuo
Abstract
The present invention addresses the problem of providing a technique for improving the antibody-inducing ability of a nasal vaccine, and a composition for nasal administration having improved antibody-inducing ability. The problem is solved by a composition for nasal administration containing: at least one substance selected from the group consisting of antigen polypeptides and polynucleotides including a coding sequence of an antigen polypeptide; and a sugar component that is a sugar and/or a sugar alcohol, wherein the content of the sugar component is more than 4.5% by mass/volume.
A pretreatment method for the analysis of a metabolite includes: a step for supplying an analysis target sample to a porous carrier to support a metabolite contained in the analysis target sample on the porous carrier; and a step for supplying a vaporized derivatization reagent to the porous carrier to which the metabolite has been supported, thereby derivatizing the metabolite.
G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
The present invention addresses the problem of providing a device for simultaneously measuring an electric signal and a contractile force by using a highly mature myocardial tissue having a 3D/oriented structure close to myocardial structure in a living body. As a solution, provided is a device for measuring the contractile force of a myocardial tissue, the device comprising a contractile unit which includes a rod-like artificial myocardial tissue having a three-dimensional structure and in which cardiomyocytes are oriented in the longitudinal direction, wherein the device is used for measuring the contractile force of the contractile unit.
The present invention addresses the problem of providing a compound that can act as a tracer to detect lymphocyte infiltration into myocardial tissue using positron emission tomography (PET) or the like. The problem is solved by a radioactive positron-emitting nuclide carbon-11 labeled compound ([11C] labeled compound) represented by general formula (I), or a pharmaceutically acceptable salt thereof. (In the formula, R1is a chlorine atom. m is an integer of 1-3. At least one of R2, R3, R4, R5, R6, or R7is a linear or branched C1-6 alkyl group, the alkyl group has radioactive positron-emitting nuclide carbon-11 [11C], and the rest are hydrogen atoms. R8 is a hydrogen atom or a linear or branched C1-6 alkyl group.)
This formed body includes a binder and a conductive coil, and the average ratio of the longest side to the shortest side in a minimum cuboid surrounding the conductive coil is 1 to 2, inclusive.
C08L 1/00 - Compositions of cellulose, modified cellulose, or cellulose derivatives
C08L 101/00 - Compositions of unspecified macromolecular compounds
H01B 1/24 - Conductive material dispersed in non-conductive organic material the conductive material comprising carbon-silicon compounds, carbon, or silicon
H01B 5/00 - Non-insulated conductors or conductive bodies characterised by their form
H01B 13/00 - Apparatus or processes specially adapted for manufacturing conductors or cables
H05K 9/00 - Screening of apparatus or components against electric or magnetic fields
The present invention addresses the problem of providing a peptide or a composition which can promote the healing of a wound at a dentin-pulp complex.
The present invention addresses the problem of providing a peptide or a composition which can promote the healing of a wound at a dentin-pulp complex.
The problem can be solved by a peptide that comprises an amino acid sequence comprising Lys-Leu-Leu-Glu-Thr-Glu-Cys-Pro-Gln (SEQ ID NO: 28), an amino acid sequence comprising Asn-Thr-Asp-Gly-Ala-Val-Asn-Phe-Gln (SEQ ID NO: 32), an amino acid sequence comprising Glu-Leu-Val-Arg-Lys-Asp-Leu-Gln-Asn (SEQ ID NO: 47), an amino acid sequence comprising Asn-Ala-Asp-Lys-Gln-Leu-Ser-Phe-Glu (SEQ ID NO: 51), an amino acid sequence having such a structure that 1 to 3 amino acid residues in the amino acid sequence represented by SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 47 or SEQ ID NO: 51 are substituted or deleted, or an amino acid sequence having such a structure that 1 to 3 amino acid residues are inserted into the amino acid sequence represented by SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 47 or SEQ ID NO: 51, the peptide having a length of 9 to 15 amino acid residues.
A sheet-shaped cell culture comprising skeletal myoblasts for treating liver dysfunction or improving liver function. A method for producing the sheet-shaped cell culture, including a step of seeding a cell population comprising skeletal myoblasts on a culture substrate, a step of forming a sheet of the cell population into a sheet to form a sheet-shaped cell culture, and a step of detaching the formed sheet-shaped cell culture from the culture substrate. A method for treating liver dysfunction, including a step of applying the sheet-shaped cell culture to a site exhibiting the liver dysfunction.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
The purpose of the present invention is to provide a method that, in a formose reaction which uses formaldehyde as a main raw material, can improve the efficiency of synthesis of sugar by increasing the rate of reaction. Provided is a method for producing sugar, said method comprising a step in which formaldehyde is used as a substrate, sugar is used as an initiator, and an oxide containing aluminum as cations is caused to act as a catalyst in a buffer solution that has an effective buffer region at a pH of 6-9.
C07C 29/141 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen-containing functional group of C=O containing groups, e.g. —COOH of a —CHO group with hydrogen or hydrogen-containing gases
C07C 33/20 - Monohydroxylic alcohols containing only six-membered aromatic rings as cyclic part monocyclic
26.
ALLOY POWDER-CONTAINING COMPOSITION AND SEMICONDUCTOR DEVICE
Provided is an alloy powder-containing composition that complies with environmental regulations, that operates at high temperatures, and that exhibits superior implementability and bonding reliability. An alloy powder-containing composition according to the present disclosure is characterized by including an alloy powder having an AgSi eutectic structure, silver (Ag) powder, and organic matter. In addition, the content of silver (Ag) relative to the total amount of the alloy powder is preferably 15-97.6 mass%, the content of the silver (Ag) powder is preferably 5-2000 parts by mass with respect to 100 parts by mass of the alloy powder, and the content of silver with respect to the total amount of the alloy powder and the silver (Ag) powder is preferably 20-99.9 mass%.
B22F 1/052 - Metallic powder characterised by the size or surface area of the particles characterised by a mixture of particles of different sizes or by the particle size distribution
B22F 7/08 - Manufacture of composite layers, workpieces, or articles, comprising metallic powder, by sintering the powder, with or without compacting of composite workpieces or articles from parts, e.g. to form tipped tools with one or more parts not made from powder
B22F 9/00 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor
The present invention provides an alloy that makes it possible to easily form a sintered body which has excellent joining reliability. An alloy according to the present disclosure is characterized by comprising a phase in which a metal element Y is in solid solution in a metal element X, wherein the metal element X is deposited on a surface via heat treatment in a gas, liquid, or solid atmosphere in which a compound is formed with the metal element Y. The metal element X is preferably deposited on the surface via a heat treatment in an oxygen atmosphere. The metal element X is preferably Ag and/or Cu. It is preferable that the metal element X contains Ag and that the metal element Y contains Si and/or Ge.
C22C 28/00 - Alloys based on a metal not provided for in groups
H01B 1/00 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors
H01B 1/02 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of metals or alloys
H01B 1/22 - Conductive material dispersed in non-conductive organic material the conductive material comprising metals or alloys
H05K 3/12 - Apparatus or processes for manufacturing printed circuits in which conductive material is applied to the insulating support in such a manner as to form the desired conductive pattern using printing techniques to apply the conductive material
28.
COMPOSITE CERAMIC, FLUORESCENT ELEMENT, LASER ILLUMINATION DEVICE, AND METHOD FOR PRODUCING COMPOSITE CERAMIC
233 as the main component of a matrix component (4), has a thickness of 220 µm or less, and has a light absorption rate of 21% or less with respect to incident light having a wavelength of 630 nm. The matrix component (4) is sintered in a manner surrounding the nitride-based fluorescent component (3), and has an internal quantum efficiency of 70% or more when being irradiated with excitation light having a wavelength of 450 nm.
The carbon dioxide recovery system (1) comprises an electrolytic reduction device (2) that generates a producer gas by reducing carbon dioxide, and a carbon dioxide separation device (3) that separates the carbon dioxide from the processed gas. The carbon dioxide separation device is provided with a first gas diffusion electrode (51), a second gas diffusion electrode (52), a liquid chamber (53) formed between the first gas diffusion electrode and the second gas diffusion electrode (52), and is configured to be supplied with an electrolytic liquid containing a compound that adsorbs and desorbs protons in an oxidation-reduction reaction, a first chamber (54) separated from the liquid chamber by the first gas diffusion electrode and configured to be supplied with the producer gas, and a second chamber (55) separated from the liquid chamber by the second gas diffusion electrode and through which the carbon dioxide separated from the producer gas flow. The electrolytic reduction device uses the carbon dioxide separated from the processed gas in the carbon dioxide separation device as a part of an input material thereof.
B01D 53/32 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
The present invention relates to a compound having light emission characteristics. The compound also has a function as a cell membrane permeation promoter for permeating a cell membrane. The compound is characterized by being represented by general formula (1). (In the formula, R1are the same or different C1-20 straight-chain aliphatic alkyl groups. R2are the same or different C1-17 straight-chain aliphatic alkyl groups or -NR322. R3 are the same or different C1-4 straight-chain aliphatic alkyl groups.)
C07C 217/58 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
Provided is an alloy powder that is compatible with environmental regulations, and is capable of forming a bonding layer that works at high temperatures and exhibits superior bonding reliability. An alloy powder according to the present disclosure has an AgSi eutectic structure and is characterized in that: one particle is selected from an image obtained by photographing a particle cross section by SEM at a magnification rate of 2,000-50,000 times, the total outer peripheral length of the particle and the length of an outer peripheral part in which the eutectic structure is present, excluding a region where there is no eutectic structure at all in a region 0.2 μm from the outer periphery in the center direction of the particle, are measured; and a method for calculating the ratio with respect to the total outer peripheral length as the ratio of the AgSi structure on the particle surface is performed on any 10 adjacent particles, and the ratio of the AgSi eutectic structure is 10% or more in at least eight of the particles.
B22F 1/00 - Metallic powderTreatment of metallic powder, e.g. to facilitate working or to improve properties
B22F 1/052 - Metallic powder characterised by the size or surface area of the particles characterised by a mixture of particles of different sizes or by the particle size distribution
B22F 7/08 - Manufacture of composite layers, workpieces, or articles, comprising metallic powder, by sintering the powder, with or without compacting of composite workpieces or articles from parts, e.g. to form tipped tools with one or more parts not made from powder
B22F 9/00 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor
233 as a main component of a matrix component (4), the composite ceramic (1) having a thickness of 220 μm or less and light absorptance of 21% or less with respect to incident light having a wavelength of 630 nm, wherein the matrix component (4) surrounding the nitride-based phosphor component (3) is sintered.
Japan as Represented by the Director-General of National Institute Institute of Infectious (Japan)
Osaka University (Japan)
Inventor
Suzuki, Ryosuke
Matsuda, Maml
Muramatsu, Masamichi
Saito, Kyoko
Fukasawa, Masayoshi
Hanada, Kentaro
Yamanaka, Atsushi
Miyazaki, Kazuo
Yamada, Misuzu
Shimizu, Jun
Abstract
The present invention aims to provide a method for testing the function of antibodies that uses safe antigens and gives results more quickly. The present invention relates to a method for determining antibody-dependent enhancement ability of antibodies, including contacting, in the presence of a test antibody, Fcγ receptor-expressing cell with single round infectious virus particles containing a gene with a region encoding a labeled protein and a region encoding non-structural (NS) proteins 1 to 5 of the yellow fever virus genome, a capsid protein of a virus, and an outer shell protein (Envelope) of a virus, wherein when the measured label is greater than that of a negative control cell, the test antibody is determined to have an antibody-dependent enhancement ability, and the like.
An ophthalmic examination apparatus includes a visual target projection system that includes a visual target presentation portion that presents a fixed visual target to left and right subject eyes, an objective measurement optical system that objectively measures eye characteristics of the left and right subject eyes, and a controller that controls each portion of the apparatus, wherein the controller measures the eye characteristics of the left and right subject eyes with the objective measurement optical system and acquires an objective refraction value as objective measurement information when fusion is attempted with left and right subject eyes with respect to a change in the convergence distance.
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/06 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing light sensitivity, e.g. adaptationSubjective types, i.e. testing apparatus requiring the active assistance of the patient for testing colour vision
A61B 3/08 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing binocular or stereoscopic vision, e.g. strabismus
A61B 3/14 - Arrangements specially adapted for eye photography
36.
OPHTHALMIC EXAMINATION APPARATUS AND OPHTHALMIC EXAMINATION METHOD
An ophthalmic examination apparatus includes a visual target projection system including a visual target presentation portion that presents a fixed visual target to left and right subject eyes, an objective measurement optical system that objectively measures eye characteristics of the left and right subject eyes, and a controller that controls each portion of the apparatus, wherein the fixed visual target is a visual target for the left eye and a visual target for the right eye that are to be respectively projected to the left and right subject eyes and have a same drawing pattern in positions where up and down direction positions to visual target flames are the same.
Provided are a new pharmaceutical composition and a method for treating and/or preventing autism spectrum disorder, fragile X syndrome, and/or an autism spectrum disorder-like symptom. A pharmaceutical composition for the treatment and/or prevention of autism spectrum disorder, fragile X syndrome, and/or an autism spectrum disorder-like symptom, comprising buprenorphine or a pharmaceutically acceptable salt thereof and/or morphine or a pharmaceutically acceptable salt thereof.
Provided is an oncolytic adenovirus (Ad) of which the basic skeleton is an Ad having a different serotype from that of an adenovirus type-5 (Ad type-5), and which has high virus yield and can exhibit a satisfactory anti-tumor effect. Also provided is a pharmaceutical composition containing the oncolytic Ad as an active ingredient. The oncolytic Ad is a recombinant oncolytic Ad characterized in that a part or the whole of E1 gene of an Ad type-5 is incorporated into an E1 region in the genome of an Ad having a different serotype from that of the Ad type-5 and a part or the whole of E4 gene of the Ad type-5 is incorporated into an E4 region in the genome of the Ad having a different serotype from that of the Ad type-5.
An object of the present invention is to provide a pharmaceutical composition for preventing and/or treating heart failure. The invention relates to a pharmaceutical composition for preventing and/or treating heart failure, comprising a compound represented by formula (1), a salt thereof, or a prodrug thereof:
An object of the present invention is to provide a pharmaceutical composition for preventing and/or treating heart failure. The invention relates to a pharmaceutical composition for preventing and/or treating heart failure, comprising a compound represented by formula (1), a salt thereof, or a prodrug thereof:
wherein
A is an optionally substituted benzene ring;
B is an optionally substituted aryl or an optionally substituted heteroaryl;
X is an oxygen atom or a sulfur atom;
Y is a nitrogen atom or a carbon atom;
of Y is a single or double bond when Y is a carbon atom, or
of Y is a single bond when Y is a nitrogen atom;
each R1 independently represents lower alkyl, or
two R1s may be bound to each other to form a spiro ring or a crosslinked structure, or
two R1s may be bound to each other to form a saturated fused heterocycle together with nitrogen and carbon atoms constituting a ring containing Y;
p is 0, 1, or 2; or
(R1)p is oxo.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
The present invention provides a sensor system capable of efficiently extracting a feature amount from a sensor detection value. An analysis unit (48) of a sensor system (1) performs at least one of using at least one value among sensor detection values as a reference value to generate an analysis value on the basis of the reference value, generating the analysis value by statistically analyzing the same type or a plurality of types of feature amounts of the sensor detection values, and generating the analysis value by referring to data indicating a relationship between the sensor detection value and a state of a structure. Disturbance influence included in the analysis value is less than disturbance influence included in the sensor detection value.
PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY (Japan)
Inventor
Kiriyama, Kahori
Hatai, Tomohiro
Hirao, Toshikazu
Amaya, Toru
Abstract
The present invention provides a composition for molding a conductive article having high conductivity. Provided is a composition for molding a conductive article, the composition containing a polythiophene compound represented by general formula (A), ammonia, and an amine compound. Also provided is a method for molding a conductive article using said composition. In general formula (A), L is an alkylene or the like. Each of M1and M2independently represents an alkyl group or a hydrogen atom. R1Ais a hydrogen atom, an alkyl group, an alkoxy group, an acyl group, or a group represented by formula (15). L1, M1cand M2care the same as L, M1and M2, respectively.
C08L 65/00 - Compositions of macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chainCompositions of derivatives of such polymers
H01B 1/12 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances organic substances
42.
VACCINE COMPOSITION FOR INDUCING ANTI-IL-23 ANTIBODY
The present invention provides a vaccine composition containing a complex of a T cell receptor antigen peptide and a B cell receptor antigen peptide and capable of inducing the production of an antibody against IL-23, wherein the B cell receptor antigen peptide is represented by the following formula (I):
The present invention provides a vaccine composition containing a complex of a T cell receptor antigen peptide and a B cell receptor antigen peptide and capable of inducing the production of an antibody against IL-23, wherein the B cell receptor antigen peptide is represented by the following formula (I):
X1-X2-X3-X4-X5-X6-X7-X8 (I)
The present invention provides a vaccine composition containing a complex of a T cell receptor antigen peptide and a B cell receptor antigen peptide and capable of inducing the production of an antibody against IL-23, wherein the B cell receptor antigen peptide is represented by the following formula (I):
X1-X2-X3-X4-X5-X6-X7-X8 (I)
wherein
X1 is S, A, G, T, K, or R,
X2 is P, A, G, S, T, K, or R,
X3 is S, A, G, T, K, or R,
X4 is Q, A, G, T, or N,
X5 is P, A, G, S, T, Q, or N,
X6 is W, A, Y, or E,
X7 is Q, A, G, T, or N, and
X8 is R, A, G, or K.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
43.
METHOD FOR PRODUCING GENOME-EDITED CELLS UTILIZING HOMOLOGOUS RECOMBINATION
A genome editing method utilizing recombination between homologous chromosomes having different bases at the target site is disclosed. Specifically, (1) a method of using cells in which the function of a gene selected from the group of Lig4 gene, PARP1 gene, XRCC1 gene, MSH2 gene, and SMARCAL1 gene is suppressed, or (2) a method of causing a single-strand break at one site in the neighboring DNA region of the target site on the chromosome of the recipient, and causing a single-strand break at one site different from the site corresponding to the site where the single-strand break is caused on the chromosome of the recipient, on the chromosome of the donor.
The present invention relates to a method for changing a hydrogel volume, the method including a step A of bringing an ionic polymer into contact with a hydrogel, which has a site having decomposition activity for the ionic polymer and a cross-linkable functional group that is capable of cross-linking with the ionic polymer through electrostatic interaction, to allow the cross-linkable functional group to cross-link with the ionic polymer, and reducing a volume of the hydrogel; and a step B of decomposing the ionic polymer cross-linking with the hydrogel by using the site having decomposition activity and discharging at least part of a decomposition product of the ionic polymer from the hydrogel to increase the hydrogel volume.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
C08L 89/00 - Compositions of proteinsCompositions of derivatives thereof
45.
OPHTHALMOLOGIC APPARATUS AND METHOD FOR EXAMINING SUBJECT EYES
An ophthalmologic apparatus includes a visual target presenting portion that presents fixation targets to subject eyes; an objective measurement optical system that objectively measures eye characteristics of the subject eyes; and a controller. Each of the fixation targets includes fusion targets depicted in a manner that allows binocular fusion while the subject eyes respectively view the fixation targets. The visual target presenting portion presents the fixation targets while changing an examination distance from the subject eyes to the fixation target when an anisometropia is induced. In the anisometropia, one subject eye is in a fully corrected condition and the other subject eye is corrected by a predetermined degree from the fully corrected condition. The controller controls the objective measurement optical system to measure the eye characteristics while the subject eyes binocularly view the fixation targets and acquire refractive values of the subject eyes as objective measurement information.
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/103 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining refraction, e.g. refractometers, skiascopes
According to one embodiment, a liquid crystal optical element includes a transparent substrate, and a liquid crystal layer which faces the transparent substrate and has a cholesteric liquid crystal and an additive exhibiting liquid crystallinity. Refractive anisotropy of the additive is less than refractive anisotropy of the liquid crystal layer.
C09K 19/30 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
Cognitive function evaluation system (100) includes motion detector (20), answer detector (30), and evaluator (40). Motion detector (20) generates frames representing three-dimensional coordinates of joints of subject (SJ) who is performing a predetermined task. The predetermined task includes a physical task and a cognitive task that requires subject (SJ) to answer questions on a cognitive examination. Motion detector (20) capture images of subject (SJ) to generate the frames. The frames are a series of frames generated in time order. Answer detector (30) detects answers to questions on the cognitive examination by subject (SJ). Evaluator (40) outputs motion features based on the frames and evaluates a cognitive function of subject (SJ) based on the motion features and the answers by subject (SJ). The motion features represent a feature of a spatial positional relationship and a feature of temporal variations, of the joints of subject (SJ) in the captured images.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
G06T 7/246 - Analysis of motion using feature-based methods, e.g. the tracking of corners or segments
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
An organ model for a medical device, which is held in a container in a state of being filled with a liquid and into which a catheter can be inserted through insertion parts provided on the container, comprise a soft member including a holding part that is held in the container, and a hard member including a plate-shaped part installed on the inner surface of the container and being integrated with the soft member, wherein the hard member is not fixed to the container, is attachable to or detachable from the soft member, and is positioned by being connected to the soft member.
An information transmission device (2) comprises: a transmission voice generation unit (12) that generates a transmission voice indicating a transmission content; an additional voice generation unit (14) that generates an additional voice; and a voice output unit (10) that simultaneously outputs the generated transmission voice and additional voice to a subject. The additional voice is a voice for improving the listening comprehension of the transmission sound by the subject as compared with a case where only the transmission sound out of the transmission sound and the additional sound is outputted to the subject.
To provide a group III nitride seed crystal substrate for use in a method for producing a group III nitride crystal having a large size and few defects. The group III nitride seed crystal substrate is used in a method for producing a group III nitride crystal, and comprises a substrate and a plurality of group III nitride seed crystals disposed over the entire flat surface of the main surface of the substrate.
A molded rigid polymer article production method includes forming a molded rigid polymer article from a rigid-polymer-dispersed liquid and drying the molded rigid polymer article. The rigid-polymer-dispersed liquid contains a polar medium and rigid polymers dispersed in the polar medium. The molded rigid polymer article is derived from the rigid polymers deposited on at least one of first and second electrodes. In the forming, the at least one includes a surface on which the rigid polymers are deposited, and convex or concave portions at the surface. The convex or concave portions are larger than a thickness of the molded rigid polymer article.
B29C 41/02 - Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped articleApparatus therefor for making articles of definite length, i.e. discrete articles
B29C 41/42 - Removing articles from moulds, cores or other substrates
Provided are a compound library generation method and the like that make it possible to construct a compound library that increases the proportion of compounds that have ability to bind to a target. A compound library generation method according to the present invention involves a computer executing processing that acquires information about a plurality of compounds stored at a first compound library, uses a learning model that has been trained to output information that indicates ability to bind to a target substance when compound information about a compound has been inputted to sort the plurality of compounds stored at the first compound library into a group of compounds that have ability to bind to a target substance and a group of compounds that do not have ability to bind to the target substance, and generates a second compound library that includes the compounds sorted into the group of compounds that have ability to bind to the target substance.
The present invention addresses the problem of providing a lung cancer biomarker and a method for using the same. The aforementioned problem is solved by a method for testing for lung cancer, the test method including (1) a step for detecting at least one protein selected from the group consisting of a protein group (A), a protein group (B), a protein group (C), a protein group (D), and a protein group (E) in a bodily fluid or extracellular vesicles of a bodily fluid collected from a subject.
An object is to provide a novel antibody or antigen-binding fragment thereof against exon 21 of human periostin. The object is achieved by an antibody or antigen-binding fragment thereof bindable to a conformational epitope on human periostin, wherein the epitope contains the amino acid sequence A represented by SEQ ID NO: 61 and the amino acid sequence B represented by any one of SEQ ID NOs: 62 to 64.
A nucleic acid encoding a miniatureized hemagglutinin complex protein, wherein the miniaturized hemagglutinin complex protein has function inhibitory activity against E-cadherin, and wherein the miniaturized hemagglutinin complex protein is selected from the group consisting of: (1) mini-HA consisting of HA1 subcomponent of SEQ ID NO: 10, HA2 subcomponent of SEQ ID NO: 4, and HA3 subcomponent fragment of SEQ ID NO: 2, (2) FL(2+3)-C consisting of HA2 subcomponent of SEQ ID NO: 4 and HA3 component with Strep-Tag (C-terminus) of SEQ ID NO: 44, (3) linked-mini (2+3)/BB of SEQ ID NO: 47, (4) linked-mini (2+3)/CB of SEQ ID NO: 48, (5) linked-mini (2+3)/CB-YFDY of SEQ ID NO: 49, and (6) linked-mini (2+3)/CB-LD/YFDY of SEQ ID NO: 50.
One drug (preparation) of the present invention is a drug for a reproductive disorder containing a silicon fine particle, an aggregate of silicon fine particles or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of reproductive disorder.
A neurofeedback system (100) for achieving an effective NF system using SWRs comprises: a brain wave signal acquisition unit (11) that acquires a brain wave signal measured in a patient; and a feedback unit (an index calculation unit 12, an output control unit 14) that calculates an index related to a sharp wave ripple included in the acquired brain wave signal in real time and allows the patient to recognize the calculated index in real time.
Provided are a polarizing agent that can selectively enhance NMR signals by the DNP-NMR method even in a reducing environment, and a method for selectively enhancing NMR signals. The present invention is a polarizing agent for use in the DNP-NMR method, the polarizing agent comprising nanodiamond particles, and the nanodiamond particles having a surface modified with a functional group capable of covalently binding to or interacting with proteins. The polarizing agent of the present invention can selectively enhance NMR signals by the DNP-NMR method even in a reducing environment.
G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
Provided is a high-function organoid composition. Also provided is a method of producing the organoid composition. The organoid composition is characterized by including: an organoid including a cell cluster of endodermal cells; and an amphiphilic block polymer having a hydrophilic block chain having a sarcosine unit and a hydrophobic block chain having a lactic acid unit. The organoid composition may be produced by culturing the endodermal cells in a culture system containing the amphiphilic block polymer. The organoid composition thus obtained can evaluate pharmacokinetics and drug toxicity, and is hence suitable for drug screening.
The purpose of the present invention is to provide a treatment for treating and/or preventing inflammatory bowel disease, such as ulcerative colitis or Crohn's disease. The present invention relates to a pharmaceutical or food composition for treating and/or preventing inflammatory bowel disease, the pharmaceutical or food composition containing a compound represented by formula (I) [in the formula, R1 is hydrogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted cycloalkyl, or a substituted or unsubstituted cycloalkenyl or a substituted or unsubstituted heterocyclyl] or a pharmacologically acceptable salt thereof.
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
61.
INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD, AND CONTROL PROGRAM
The problem addressed by the present invention is to recognize a change of the condition of a subject. An information processing device (1) comprises: a data acquisition unit (21) that acquires medical examination data about the subject; a classification unit (22) that inputs the acquired medical examination data about the subject to a classification model that can classify the subject into any one of a plurality of expression types on the basis of the medical examination data, and classifies the subject into any one of the plurality of expression types; and a subject transition information output unit (23) that outputs subject transition information indicating a transition of the subject from a first classification result to a second classification result.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
This medical instrument processing member (100) capable of improving workability comprises a heating unit (2). The heating unit (2) has a first internal space (2a). The heating unit (2) is a bag-shaped member including a heat-generating element (4). In the heating unit (2), a first opening (2b) continued to the first internal space (2a) of the heating unit (2) is formed. The outer peripheral shape of the heating unit (2) may be cylindrical. The heat-generating element (4) may react with air to generate heat by oxidation. The medical instrument processing member (100) may comprise a wiping unit (1). The wiping unit (1) may be connected to the heating unit (2).
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/12 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with cooling or rinsing arrangements
A61M 5/44 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for cooling or heating the devices or media
In a distributed feedback semiconductor laser element, a multi-layered structure includes a GaN substrate, an n-type semiconductor layer, an active layer, and a p-type semiconductor layer, and a ridge waveguide is formed. A first diffraction grating is formed adjacent to and on both sides of the ridge waveguide. A depth d of a groove of the first diffraction grating is included in the range of 50 nm d≤200 nm, and a duty ratio duty is included in the range of an inequality (1) using constants a, b, c, and n defined for the order of the diffracted light.
In a distributed feedback semiconductor laser element, a multi-layered structure includes a GaN substrate, an n-type semiconductor layer, an active layer, and a p-type semiconductor layer, and a ridge waveguide is formed. A first diffraction grating is formed adjacent to and on both sides of the ridge waveguide. A depth d of a groove of the first diffraction grating is included in the range of 50 nm d≤200 nm, and a duty ratio duty is included in the range of an inequality (1) using constants a, b, c, and n defined for the order of the diffracted light.
-
d
-
c
a
n
+
b
≦
duty
≦
d
-
c
a
n
+
b
(
1
)
Provided is an isotope enrichment and separation method for concentrating and separating an isotopic element efficiently and at low cost even when the element has no gas compound. According to this isotope enrichment and separation method, with which a target isotope is concentrated and separated from an element in which different isotopes are present: an aqueous solution of an element compound in which different isotopes are present is prepared and then set in a centrifugal separator; a centrifugal force of the centrifugal separator is caused to act on the aqueous solution to cause the isotopes in the aqueous solution to migrate so as to change the concentration distribution of the isotopes in the aqueous solution in a gradual manner; and the aqueous solution located at the position of the desired isotope in the concentration distribution is separated out to perform concentration and separation of the target isotope.
This laminate comprises: a piezoelectric layer containing lead; a metal layer laminated on the piezoelectric layer and containing vanadium; and a first ferromagnetic layer laminated on the piezoelectric layer with the metal layer interposed therebetween. As a result of intensive research by the present inventors, it has been found that the induced magnetic anisotropy energy of the first ferromagnetic layer depends on the sample structure of the first ferromagnetic layer and the metal layer containing vanadium. By utilizing this point, a binary property can be controlled by adjusting the sample structure of the first ferromagnetic layer or the metal layer and changing the induced magnetic anisotropy energy. Thus, with the laminate, it is possible to easily control a binary property.
The present invention found that, for example, inhibiting phosphorylation of a Ser residue in Regnase-1 is effective in treating and/or preventing diseases. The invention also found that, for example, inhibiting the binding of Regnase-1 with at least one factor selected from the group consisting of TBK1, IKKi, Act-1, IKK, and IRAK is effective in treating and/or preventing diseases.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 7/64 - Cyclic peptides containing only normal peptide links
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
The present invention provides an Al-ND-based composite material in which nanodiamond (ND) particles are dispersed in an aluminum (Al)-based metal matrix.
B22F 1/18 - Non-metallic particles coated with metal
B22F 3/105 - Sintering only by using electric current, laser radiation or plasma
B22F 3/24 - After-treatment of workpieces or articles
B22F 9/04 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using physical processes starting from solid material, e.g. by crushing, grinding or milling
C22C 1/059 - Making alloys comprising less than 5% by weight of dispersed reinforcing phases
69.
GRAPHENE GRID, METHOD FOR PRODUCING GRAPHENE GRID, AND METHOD FOR ANALYZING STRUCTURAL ANALYSIS TARGET SUBSTANCE
A graphene grid that can reduce or prevent uneven distribution, uneven orientation, and the like of a structural analysis target substance, and can capture the structural analysis target substance with high efficiency and analyze the structural analysis target substance with high resolution, in structural analysis by cryo-electron microscopy. To achieve the above object, the graphene grid has a graphene surface onto which a functional group containing at least one of a silicon atom or a phosphorus atom is introduced.
Provided is an irradiation device that is capable of effectively suppressing activities of insect pests. An irradiation device (100) includes: a detection section (31) that detects an insect which is an irradiation target; an identification section (32) that identifies position information of the irradiation target; and an irradiation section (1) that, based on the position information, irradiates the irradiation target with shooting laser light (L2) while targeting a specific part of the irradiation target.
A01M 1/22 - Stationary means for catching or killing insects by electric means
G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
71.
METHOD FOR GENERATING SPECTRAL DATA PERTAINING TO MICROPARTICLE SAMPLE, METHOD FOR ANALYZING MICROPARTICLES, METHOD FOR DISTINGUISHING MICROPARTICLES, METHOD FOR ASSESSING WHETHER CANCER-CELL-DERIVED EXOSOMES ARE PRESENT, SUBSTRATE FOR MEASURING SPECTRUM OF MICROPARTICLES, DEVICE FOR MEASURING SPECTRUM OF MICROPARTICLES, AND APPARATUS FOR MEASURING SPECTRUM OF MICROPARTICLES
National University Corporation Hokkaido University (Japan)
Osaka University (Japan)
Inventor
Ryuzaki, Sou
Matsuda, Rintaro
Taniguchi, Masateru
Komoto, Yuki
Abstract
A method for generating spectral data according to the present invention involves generating spectral data pertaining to a microparticle sample that includes at least one microparticle, wherein: the method includes a step for acquiring a measurement spectrum from microparticles disposed within a through-hole in a substrate; the through-hole has an inclined structure in which the width continuously decreases from one surface of the substrate toward the other surface thereof; at least part of the inner surface of the through-hole is configured from a metal that exhibits plasmon resonance; and in the step for acquiring the measurement spectrum, the measurement spectrum is acquired while the interior of the through-hole is irradiated with light.
The present invention provides: a prophylactic or ameliorating agent for cachexia, which contains a phospholipid and/or a lysophospholipid as an active ingredient; and a method for screening for a substance capable of ameliorating cachexia. The prophylactic or ameliorating agent for cachexia according to the present invention is effective not only against cancer cachexia but also against cachexia induced by a disease other than cancer, can suppress the decrease in a skeletal muscle mass, can suppress fat atrophy, and can suppress the expression of inflammatory cytokines.
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A spectrometry device (1) according to an embodiment of the present invention comprises: a first fiber unit (70) into which irradiation light enters; a portable unit (80) to which the first fiber unit is connected; a spectroscope (50) which diffracts a signal light; a second fiber unit (40) which is connected to the portable unit (80) and in which a plurality of second fibers are arranged adjacent to each other on an incident end surface, and a plurality of fibers are arranged in a multi-line shape so as to be spaced apart on an emission end surface; and a processing unit that generates a spectral image of a sample from a detection result of a two-dimensional array photodetector by referring to the arrangement relationship between the plurality of fibers on the incident end surface and the emission end surface of the second fiber unit (40).
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
G01J 3/36 - Investigating two or more bands of a spectrum by separate detectors
The present invention addresses the problem of providing: a protein that acts as a scintillator; and a method for designing a protein that acts as a scintillator. According to the present invention, a use of a β-barrel-type fluorescent protein as a scintillator is provided, wherein the β-barrel-type fluorescent protein has a fluorescence peak at 500 nm or less. According to the present invention, a method for designing a protein that acts as a scintillator is also provided, the method comprising (A) a step for identifying a specific amino acid residue in an amino acid sequence for a β-barrel-type fluorescent protein being mutated and (B) a step for constructing, on the basis of the amino acid sequence for the protein being mutated, an amino acid sequence having a structure such that the amino acid residue identified in the step (A) is substituted by another specific amino acid residue.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C12M 1/00 - Apparatus for enzymology or microbiology
C12N 1/13 - Unicellular algaeCulture media therefor modified by introduction of foreign genetic material
C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
The present disclosure provides an apparatus and a method for manufacturing a composite. In one aspect, the present disclosure provides a method for manufacturing a formulation comprising a first component and a second component. This method includes: a step for preparing a series of flow paths in which a first flow path through which a first fluid flows at a first flow velocity and a second flow path through which a second fluid flows at a second flow velocity are combined at a merging portion to form a third flow path through which a third fluid flows at a third flow velocity; a step in which the first component is injected into the first flow path at a first time; and a step in which the second component is injected into the second flow path at a second time. The first time and the second time are set so that the first component and the second component reach the merging portion at a timing when the components are mixed.
B01F 35/92 - Heating or cooling systems for heating the outside of the receptacle, e.g. heated jackets or burners
B01F 35/213 - Measuring of the properties of the mixtures, e.g. temperature, density or colour
B01F 35/221 - Control or regulation of operational parameters, e.g. level of material in the mixer, temperature or pressure
B01J 2/10 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
B01F 101/22 - Mixing of ingredients for pharmaceutical or medical compositions
76.
CANCER EXAMINATION METHOD AND CANCER TREATMENT AGENT
Provided is a biomarker useful for the diagnosis of cancer and the development of new drugs. Further provided are a cancer examination method, a treatment agent, and a reagent for studies of cancer, in each of which the biomarker is used. A useful biomarker is provided by identifying a protein that is expressed on the surface of the membrane of an extracellular vesicle (EV) in a cancer-specific manner. The cancer examination method includes detecting a protein (biomarker) that is expressed, in a cancer-specific manner, on the surface of the membrane of an EV contained in a collected body fluid specimen to detect a cancer-specific EV. An antibody against a protein expressed on the surface of the membrane of an EV in a cancer-specific manner can be used in a cancer examination method, a cancer treatment agent, and a reagent for studies of cancer.
OSAKA RESEARCH INSTITUTE OF INDUSTRIAL SCIENCE AND TECHNOLOGY (Japan)
Inventor
Kitano, Katsuhisa
Ikawa, Satoshi
Abstract
This sterilization device (1) comprises: a first container (12) that accommodates an object (A01); a first decompression unit (14) that decompresses the first container; and a supply unit (15) that supplies a pernitric acid gas to the object placed under a decompressed condition provided by the first decompression unit. The sterilization device can sterilize deep portions of the object.
Provided is a wavelength conversion element in which high-quality crystal part can be utilized by a simple configuration. This wavelength conversion element comprises a substrate having a main surface, and an optical waveguide disposed on the main surface of the substrate, a core of the optical waveguide including a polar member having a second-order nonlinear optical constant and a first non-polar member disposed adjacent to the polar member in a direction parallel to the main surface of the substrate, and one or both side surfaces of the polar member and the first non-polar member being in contact with each other in a cross section orthogonal to the optical axis of the optical waveguide.
The present disclosure provides an apparatus and a method for taking out a particular fraction from a flow path. More particularly, in one aspect, the present disclosure provides a method for taking out a particular fraction from a flow path. The method includes: a step for flowing a component through the flow path; a step for taking out a fraction from the collection part on the flow path by means of a dispenser provided with a valve; and a step for distributing the fraction to the receiving part. In one embodiment, the collection part is positioned in a middle portion of the flow path (a portion that is neither an inflow port nor an outflow port of the flow path).
B01F 35/213 - Measuring of the properties of the mixtures, e.g. temperature, density or colour
B01F 35/221 - Control or regulation of operational parameters, e.g. level of material in the mixer, temperature or pressure
B01J 2/10 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
B01J 4/00 - Feed devicesFeed or outlet control devices
B01J 13/02 - Making microcapsules or microballoons
B01F 101/04 - Mixing biocidal, pesticidal or herbicidal ingredients used in agriculture or horticulture, e.g. for spraying
Provided is a method for detecting an abnormal cell having a gene mutation, the method comprising: a step for amplifying a region corresponding to a region comprising a nucleotide sequence lying between a nucleotide located at position-1,316 and a nucleotide located at position-1,663 in SEQ ID NO:1 and/or a region corresponding to a region comprising a nucleotide sequence lying between a nucleotide located at position-1,931 and a nucleotide located at position-2,642 in SEQ ID NO: 1 to produce an amplification product, wherein SEQ ID NO:1 is included in genomic DNA derived from a peripheral blood mononuclear cell of the patient; and a step for determining the nucleotide sequence for the amplification product and detecting a nucleotide mutation. In the method, the presence of the lesion is indicated when the nucleotide mutation is detected, and the amplification is performed by a PCR using a primer having no additional sequence.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The purpose is to provide a novel luminescence-related gene (nucleic acid, vector for expression) capable of imparting stronger luminescence than by known luminescence-related genes to an organism (in particular, a plant). Provided is a nucleic acid containing at least one base sequence selected from: a base sequence encoding a protein containing an amino acid sequence represented by SEQ ID NO: 1 or an amino acid sequence having 90% or more sequence identity with a sequence represented by SEQ ID NO: 1; a base sequence encoding a protein containing an amino acid sequence represented by SEQ ID NO: 2 or 3 or an amino acid sequence having 90% or more sequence identity with a sequence represented by SEQ ID NO: 2 or 3; a base sequence encoding a protein containing an amino acid sequence represented by SEQ ID NO: 4 or 5 or an amino acid sequence having 90% or more sequence identity with a sequence represented by SEQ ID NO: 4 or 5; and a base sequence encoding a protein containing an amino acid sequence represented by SEQ ID NO: 6 or an amino acid sequence having 90% or more sequence identity with a sequence represented by SEQ ID NO: 6.
One purpose of the present invention is to provide a resin film and a metal-clad laminate, each of which enables the production of a printed wiring board that has excellent dimensional stability, while being reduced in transmission loss. Another purpose of the present invention is to provide a method for producing a resin film that enables the production of a printed wiring board that has excellent dimensional stability, while being reduced in transmission loss. The present invention relates to a resin film 7 which comprises a polyimide film 70 and a PTFE film 71 that is directly superposed on the polyimide film 70. With respect to the resin film 7, the peeling strength at the time when the PTFE film 71 is peeled is 0.5 N/mm or more.
B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
B29C 65/02 - Joining of preformed partsApparatus therefor by heating, with or without pressure
B32B 15/08 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin
A welding inspection method includes a step S102 of removing an impurity at a surface of a weld with a surface treatment apparatus, a step S110 of irradiating the surface of the weld from which the impurity has been removed with transmission laser light, a step S120 of detecting reflected ultrasound reflected by a lower surface of a base material, and a step S150 of determining whether or not there is an internal defect in the weld based on a result of detection of reflected ultrasound.
G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
B23K 31/12 - Processes relevant to this subclass, specially adapted for particular articles or purposes, but not covered by any single one of main groups relating to investigating the properties, e.g. the weldability, of materials
A permanent magnet-type rotary electric machine comprises: a stator including: a stator core having a plurality of stator teeth formed circumferentially; stator coils arranged in the respective bottoms of a plurality of stator slots formed between the stator teeth and wound on the stator teeth in a concentrated winding manner; and stator magnets arranged near the respective openings of the plurality of stator slots, a first rotor having a plurality of pole pieces and disposed coaxially with the stator to face the stator magnets; and a second rotor having a plurality of permanent magnets and disposed coaxially with the first rotor to face the first rotor, wherein the circumferential width of stator teeth positioned between the adjacent two of the stator magnets is narrower than the circumferential width of the stator slots.
An additive manufacturing apparatus includes: a chamber; a gas supply device that supplies an ambient gas into the chamber; an irradiation device that irradiates a molding region with an energy beam in order to mold a three dimensional molding object, the molding region being provided with a powder bed fusion on which a powder is spread in the chamber; and a controller that performs control related to additive manufacturing of the molding object, wherein the controller is configured to increase a pressure of the ambient gas in the chamber to be higher than an atmospheric pressure when the molding object is molded.
This boron compound is represented by formula (1). In formula (1), X1and X2are each independently selected from among electron-withdrawing groups, Y1and Y2are each independently selected from among hydrogen and electron-donating groups, with hydrogen not being selected for both simultaneously, R1 is selected from among C1-24 organic groups, the C1-24 organic group may have a substituent, and n is selected from among the integers from 0 to 2.
C07D 215/06 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
In a method for creating isotope distribution data, samples for analysis having different concentrations of metabolites are prepared as samples containing metabolites of cells cultured in a medium containing a substrate labeled with a stable isotope, mass spectrometry is performed on each under the same analysis condition, mass spectrum data is analyzed for each to identify the type of the metabolites, and there are determined the number of metabolites included in a metabolite group made of unlabeled metabolites and/or isotopic isomers, and the signal intensities of mass peaks corresponding to all isotope isomers included in the metabolite group. The number of metabolites corresponding to all types of metabolites and the signal intensity are compared among the samples to select a sample for analysis for obtaining the isotope distribution, and data on the isotope distribution of the metabolite is integrated to create the isotope distribution data of the metabolite.
A method for separating components using a supercritical fluid chromatograph, including: injecting a sample into a mobile phase containing a supercritical fluid and a modifier to introduce the sample into a column; and separating components in the sample during passing through the column; wherein the sample contains an oligonucleotide as a target component; the supercritical fluid contains carbon dioxide; and the modifier contains a solution containing at least one selected from the group consisting of ammonium, an alkylamine, and an amino alcohol, and an acid.
Provided is a technique for examining an autoimmune disease. This method for examining an autoimmune disease involves (1) a step for examining the presence or absence of endogenous human herpesvirus 6B in genomic DNA of a biological sample sampled from a subject.
A solid state welding apparatus comprises a pair of compression bars, a pair of electrodes disposed around the pair of compression bars, respectively, and a controller. The controller passes a first current through the pair of electrodes while controlling the pair of compression bars to cause a first load to act on each of first and second workpieces to bring the workpieces into contact with each other, and subsequently passes a second current larger than the first current through the pair of electrodes while controlling the pair of compression bars to cause a second load to act on each of first and second workpieces.
B23K 11/24 - Electric supply or control circuits therefor
91.
WALL THICKNESS ESTIMATION METHOD, RECORDING MEDIUM, TRAINING METHOD, MODEL CONSTRUCTION METHOD, WALL THICKNESS ESTIMATION DEVICE, AND WALL THICKNESS ESTIMATION SYSTEM
A wall thickness estimation method includes: obtaining behavioral information that is based on a video in which an organ wall or a blood vessel wall is captured using four-dimensional angiography, the behavioral information being numerical information about changes over time in a position of each of a plurality of predetermined points in the organ wall or the blood vessel wall; generating estimation information using a model trained to take as an input an image indicating a physical parameter based on the behavioral information obtained in the obtaining and output an index indicating a thickness at each of the plurality of predetermined points in the organ wall or the blood vessel wall, the estimation information being information visualizing the thickness; and outputting the estimation information generated in the generating.
A resistance spot joining method includes: a protrusion forming step of forming a protrusion on at least one of a first workpiece and a second workpiece by pressing the first and second workpieces with a first load by a pressing shaft and a pressing member; a load reducing step of reducing an area of contact between the first and second workpieces by reducing a pressing force from the pressing shaft and the pressing member such that a second load is applied to the first and second workpieces; a current applying step of applying a current to the first and second workpieces; and a joining step of joining contact interfaces of the first and second workpiece to each other by pressing the first and second workpieces with a third load.
A solid state welding apparatus comprises a pair of compression bars, a pair of electrodes disposed around the pair of compression bars, respectively, and a controller. The controller controls the pair of compression bars to cause a first load to act on each of the first and second workpieces, subsequently controls the pair of compression bars to subject compressive force to load removal to cause a second load smaller than the first load to act on the first and second workpieces, and subsequently passes a current through the pair of electrodes to remove an impurity on a metal surface.
A structured illumination microscope according to the present embodiment comprises: an excitation light source for generating excitation light; an activation light source that generates activation light to activate a fluorescent substance; an objective lens that focuses the excitation light onto a sample S; a structured illumination optical system that illuminates the sample using the excitation light as a structured illumination pattern; an activation optical system that irradiates the sample with activation 2 through the objective lens; and an imaging optical system that detects fluorescence generated at the sample via the objective lens to capture a fluorescent image of the sample.
This soldering device comprises: a solder joint part-forming device that has a soldering iron and forms a solder joint part in a soldering target area; an imaging device that images the solder joint part formed in the target area from a prescribed direction; an illumination device that illuminates the solder joint part formed in the target area from the prescribed direction; and a control device. The control device: causes the imaging device to perform imaging in a state in which the illumination device is providing illumination, thereby obtaining a first image of the solder joint part; causes the imaging device to perform imaging in a state where the illumination device has stopped illuminating, thereby obtaining a second image of the solder joint part; creates a brightness difference image which indicates a difference in brightness between the first image and the second image; and makes a determination about an excess failure and/or a shortage failure of the solder joint part, on the basis of the brightness difference image.
Provided are an information processing method, a computer program, an information processing system, and an information terminal device that achieve safe and effective circulation of medical data. An information processing method according to the present invention involves a computer executing processing that receives a purchase condition for a set of non-fungible tokens (NFTs) issued for access to the medical data of patients, outputs retrieval results for a set of NFTs that match the received purchase condition and a sales condition for the retrieved set of NFTs, receives a purchase request that designates a set of NFTs to be purchased from the retrieval results, transfers the set of NFTs to a purchaser in response to the purchase request, and gives compensation that corresponds to the transfer of the set of NFTs to the registrant registered to each of the NFTs included in the set.
Y1-YX1-x1-xN, and on which the Group III nitride semiconductor layer, the active layer, and the electron blocking layer are mounted, wherein X is greater than 0 and less than or equal to 1. In the active layer, the Al composition G is equal to or greater than Y but less than (Y+0.04), and the compositional difference between the maximum Al composition of the electron blocking layer and the Al composition of the active layer is 0.18 or more.
Disclosed is a bispecific antibody that recognizes CCR8 as an antigen. It was found that the bispecific antibody has cytotoxic activity against CCR8-expressing cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided are: a coating composition which has enhanced coatability and solubility in solvents and contains POSS with alkyl groups introduced; a method for producing a coated article using the coating composition; and a produced coated article. The present invention relates to a coating composition containing a silsesquioxane derivative which has a silsesquioxane skeleton having a polyhedral structure and in which a plurality of alkyl groups having different numbers of carbon atoms are bonded to silicon atoms. The coating composition can be applied to a substrate to produce a coated article. This produced coated article has a substrate and a coating, formed on the surface of the substrate, that contains a silsesquioxane derivative which has a silsesquioxane skeleton having a polyhedral structure and in which a plurality of alkyl groups having different numbers of carbon atoms are bonded to silicon atoms.
Provided are a graphene biosensor having high resistance to foreign substances while maintaining ultra-high sensitivity characteristics of graphene, and a method for using the graphene biosensor. Provided is a graphene biosensor 1 for detecting a measurement object gas 200 included in a liquid sample 100, wherein the graphene biosensor comprises: a substrate 10; a graphene layer 30 provided on the substrate 10, comprising at least one layer of graphene, and having a graphene layer principal surface 32 on the liquid sample 100 side; a drain electrode 21 electrically connected to the graphene layer 30; a source electrode 22 electrically connected to the graphene layer 30; and a gas-permeable layer 40 that comprises a gas-permeable material that transmits the measurement object gas 200, covers the graphene layer principal surface 32, and has a permeable layer principal surface 42 on the liquid sample 100 side.
